Clinical trials: Malaria, completed
Malaria
Pan-Malaria Transmission-Blocking Vaccine AnAPN1
Malaria is still responsible for more than 627,000 deaths each year, predominantly among children under 5 years old. Current reductions in deaths have stagnated, and additional setbacks for malaria control programs due to the…
- Trial name
- PamTBVac (NCT05905432)
- Testing
- Vaccine AnAPN1
- Where
- Gabon
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Centre de Recherche Médicale de Lambaréné
Uncomplicated P. Falciparum Malaria
SPK Study in Afghanistan
In Afghanistan, studies over the past 15 years have shown a high degree of Plasmodium falciparum resistance to chloroquine. In 2003 the high failure rate of chloroquine against falciparum malaria led the national malaria…
- Trial name
- NCT01707199
- Testing
- Artesunate + Sulphadoxine-pyrimethamine
- Where
- Afghanistan
- Volunteers
- 83 people
- Sponsor
- University of Oxford
Malaria
Blood-Stage Plasmodium Vivax Cell Bank
Background: Malaria is caused by a parasite (a type of germ called P. vivax) that is carried by mosquitoes. The disease is transmitted to people when they are bitten by infected mosquitoes.
- Trial name
- NCT05095272
- Testing
- HMPBS02-Pv
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Respiratory Infections
A Trial of Seasonal Malaria Chemoprevention Plus Azithromycin in African Children
The primary objective of this study is to determine whether addition of azithromycin (AZ) to Seasonal Malaria Chemoprevention (SMC) using sulphadoxine/pyrimethamine (SP) +amodiaquine (AQ) will provide an additional reduction in…
- Trial name
- SMCAZ (NCT02211729)
- Testing
- Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin
- Where
- 2 sites in Burkina Faso, Mali
- Volunteers
- 22,090 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria
Safety and Efficacy of Recommended Antimalarial in the Democratic Republic of the Congo
Despite all efforts, malaria remains a public health concern, in particular in the Democratic Republic of the Congo (DRC). The National Malaria Control program recommends artemisinin-based combination treatments (ACTs), in…
- Trial name
- TET2020 (NCT04618523)
- Testing
- Artesunate-amodiaquine, Artemether-lumefantrine
- Where
- 6 sites in Democratic Republic of the Congo
- Volunteers
- 1,117 people
- Sponsor
- Ministry of Public Health, Democratic Republic of the Congo
Uncomplicated Plasmodium Falciparum Malaria
Triple Artemisinin-based Combination Therapy for Delaying Drug Resistance Development - a Randomized Clinical Trial
Background: Artemisinin resistance has emerged in parts of Southeast Asia, and there are reports in Africa of reduced susceptibility of Plasmodium falciparum parasites against artemisinin-based combination therapy (ACT).
- Trial name
- 3ACT (NCT05764746)
- Testing
- Artemether-lumefantrine and Amodiaquine Drug Combination, Artemether-lumefantrine then Artesunate amodiaquine, Artemether-lumefantrine
- Where
- 2 sites in Tanzania
- Volunteers
- 384 people
- Sponsor
- Muhimbili University of Health and Allied Sciences
Malaria
Can Treatment of Malaria be Restricted to Parasitologically Confirmed Malaria?
The investigators performed a prospective study, in order to assess the feasibility and safety of restricting antimalarials to rapid diagnostic test (RDT)-confirmed cases in children aged 5 to 15 years-old
- Trial name
- NCT00913146
- Where
- Benin
- Volunteers
- 484 people
- Sponsor
- Institut de Recherche pour le Developpement
Anemia
RBC Transfusion in Severe Anemia With Lactic Acidosis
The hypothesis of this study is that prolonged-storage RBCs are not inferior to short-storage RBCs for the time required to clear elevated blood lactate levels in children with severe anemia.
- Trial name
- TOTAL (NCT01586923)
- Testing
- RBC transfusion
- Where
- Uganda
- Volunteers
- 290 people
- Sponsor
- Massachusetts General Hospital
Uncomplicated Malaria
A Randomized Controlled Trial on Malaria Primaquine Treatment in Timika, Indonesia (TRIPI)
Plasmodium vivax can form dormant liver stages that reactivate weeks or months following an acute infection. Recurrent infections can be associated with a febrile illness, a cumulative risk of severe anaemia, and even mortality.
- Trial name
- TRIPI (NCT02787070)
- Testing
- PQ supervised, PQ unsupervised
- Where
- Indonesia
- Volunteers
- 420 people
- Sponsor
- Menzies School of Health Research
Acute Non-falciparum Malaria
Treatment of Non-falciparum Malaria
Patients with non-falciparum infection will be given artemether-lumefantrine for three days and will be followed up for 28 days. Besides efficacy and safety evaluations a substudy on immunology will be performed.
- Trial name
- NCT00725777
- Testing
- artemether-lumefantrine
- Where
- Gabon
- Volunteers
- 40 people
- Sponsor
- Albert Schweitzer Hospital
Malaria
Improved Clinical and Microscopy Diagnosis at Primary Health Care in Tanzania
General objective: To improve the quality of fever case management in children in government health facilities in Tanzania Hypothesis:The training of health workers, as well as provision, training and use of microscopes for…
- Trial name
- NCT00687895
- Testing
- Clinical algorithm and microscopy diagnosis of malaria
- Where
- Tanzania
- Volunteers
- 3,131 people
- Sponsor
- Muhimbili University of Health and Allied Sciences
Malaria
Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen
This study is being done to assess the possibility of the potential integration of malaria vaccine into the EPI regimen. It will evaluate whether the malaria vaccine is safe and immunogenic in infants aged 6 to 10 weeks at first…
- Trial name
- NCT00436007
- Testing
- GSK 257049, Tritanrix™ HepB/Hib, Rouvax™
- Where
- 3 sites in Gabon, Ghana and 1 more
- Volunteers
- 511 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria
Food-Effect Bioavailability Study of AQ-13, a Candidate Antimalarial
The purpose of this study is to test the safety of a 2100 mg dose of AQ-13, a new candidate antimalarial active against drug-resistant P.
- Trial name
- NCT00455494
- Testing
- AQ-13
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Tulane University Health Sciences Center
Acute Falciparum Malaria
Efficacy, Safety, and Tolerability of Dihydroartemisinin-piperaquine + Mefloquine Compared to Dihydroartemisinin-piperaquine or Artesunate-mefloquine in Patients With Uncomplicated Falciparum Malaria in Cambodia
Background: Malaria is an illness caused by a parasite that enters people s bodies when a mosquito bites them. It can cause fevers, headaches, body aches, and weakness. If not treated, it can make some people very ill.
- Trial name
- NCT02612545
- Testing
- Dihydroartemisinin-piperaquine (DHA-PPQ), Mefloquine (MQ)
- Where
- Cambodia
- Volunteers
- 216 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Falciparum
Malaria Transmission Studies in Mali
Background: Malaria is an illness caused by a parasite spread by mosquitoes. When a mosquito bites a person who is infected with a kind of parasite called a gametocyte, it is able to spread the infection to another person.
- Trial name
- NCT01829737
- Where
- United States
- Volunteers
- 534 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Artemether-lumefantrine for Treatment of P. Falciparum Malaria in Brazil
This is an in vivo evaluation of drug efficacy performed in Cruzeiro do Sul, in the state of Acre, Brazil. A total of 81 participants ≥5 years old with parasitological confirmation of P.
- Trial name
- NCT02600767
- Testing
- Artemether-lumefantrine combination
- Where
- Brazil
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Pneumonia, Malaria
Zambia Integrated Management of Malaria and Pneumonia Study
The purpose of the study is to demonstrate the effectiveness and feasibility of community-based management of pneumonia and malaria by community health workers (CHWs) in a rural district of Zambia.
- Trial name
- ZIMMAPS (NCT00513500)
- Testing
- Coartem and amoxicillin, Coartem
- Where
- Zambia
- Volunteers
- 3,125 people
- Sponsor
- Boston University
Healthy Volunteers
Study To Evaluate Safety, Tolerability, and Pharmacokinetics of MAM01 in African Population
This study will test a new drug (MAM01) to find which doses are safe and could help prevent people from getting malaria for at least 4 months. The study will take place in parts of Africa where malaria is common.
- Trial name
- NCT06408857
- Testing
- MAM01 300 mg SC, MAM01 300 mg IM, MAM01 2000 mg IV
- Where
- 2 sites in Uganda
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Gates Medical Research Institute
MALARIA, FALCIPARUM
In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated P. Falciparum Malaria
This study was designed to determine the efficacy of both artemether-lumefantrine and artesunate-amodiaquine (but not to compare the efficacies of the two drugs) for the treatment of uncomplicated Plasmodium falciparum malaria at…
- Trial name
- NCT02637128
- Testing
- artemether-lumefantrine (AL), artesunate-amodiaquine (ASAQ)
- Where
- Malawi
- Volunteers
- 452 people
- Sponsor
- Centers for Disease Control and Prevention
Plasmodium Falciparum Malaria, Pregnancy Malaria
Clinical Performance of the Histidine Rich Protein 2 (HRP2) Highly Sensitive Rapid Diagnostic Test (HS-RDT) for Malaria Diagnosis in Pregnant Women in Papua New Guinea
Malaria during pregnancy remains an important public health issue in endemic countries. Most cases of malaria in pregnant women are asymptomatic, and can contribute to adverse outcomes, such as maternal and neonatal anaemia as…
- Conditions
- Plasmodium Falciparum Malaria, Pregnancy Malaria, Diagnoses Disease
- Trial name
- NCT03462615
- Testing
- HS-RDT
- Where
- Papua New Guinea
- Volunteers
- 930 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.